Holen Sie sich die Stockscreener-App
21.60
1.46%
-0.32
Schlusskurs vom Vortag:
$21.92
Offen:
$21.6
24-Stunden-Volumen:
58,806
Relative Volume:
0.54
Marktkapitalisierung:
$312.68M
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$1.76B
KGV:
0.182
EPS:
118.674
Netto-Cashflow:
$-149.23M
1W Leistung:
-6.41%
1M Leistung:
+47.24%
6M Leistung:
+59.06%
1J Leistung:
+48.25%
1-Tages-Spanne:
$21.37
$22.24
1-Wochen-Bereich:
$21.37
$25.29
52-Wochen-Spanne:
$10.80
$25.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Vergleichen Sie INBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
21.60 | 317.31M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx Biosciences Inc. stock prediction for this weekFree Earnings Play Trade Plan With Alerts - Newser
What are analysts’ price targets for Inhibrx Biosciences Inc. in the next 12 monthsIdentify winners with top-tier analysis - jammulinksnews.com
Inhibrx Biosciences Inc. Stock Analysis and ForecastAccelerated capital growth - jammulinksnews.com
What makes Inhibrx Biosciences Inc. stock price move sharplyRemarkable growth - jammulinksnews.com
What analysts say about Inhibrx Biosciences Inc. stockGet real-time alerts on high-potential stocks - jammulinksnews.com
Does Inhibrx Biosciences Inc. stock perform well during market downturnsTriple-digit wealth increases - jammulinksnews.com
Is Inhibrx Biosciences Inc. stock overvalued or undervaluedAmplify your gains with low-risk picks - jammulinksnews.com
Tools to assess Inhibrx Biosciences Inc.’s risk profileGrowth Summary Based on Market Positioning - Newser
Does Inhibrx Biosciences Inc. qualify in momentum factor screeningLow Risk Stock Trade Opportunity Analysis - Newser
Risk adjusted return profile for Inhibrx Biosciences Inc. analyzedVolume Based Swing Signal Prediction Map - Newser
What moving averages say about Inhibrx Biosciences Inc.2-Day Signal Watch with Forecast Outcome - Newser
Inhibrx Biosciences Inc. Company Revenue and Profit Trends: A Deep DiveFree Daily Volume Spike Trading Signals - Newser
What is the risk reward ratio of investing in Inhibrx Biosciences Inc. stockConsistent high-performance stocks - jammulinksnews.com
New Product Launches: Will They Boost Inhibrx Biosciences Inc. Stock in 2025Momentum-Based Prediction for Quick Returns - Newser
What are Inhibrx Biosciences Inc. company’s key revenue driversNavigate market shifts with confidence - jammulinksnews.com
Should I hold or sell Inhibrx Biosciences Inc. stock in 2025Robust investment performance - jammulinksnews.com
When is Inhibrx Biosciences Inc. stock expected to show significant growthCapitalize on market momentum for profits - jammulinksnews.com
What institutional investors are buying Inhibrx Biosciences Inc. stockGet alerts on high-potential market moves - jammulinksnews.com
Will Inhibrx Biosciences Inc. outperform the marketConservative Asset Allocation Risk Analysis - newser.com
Has Inhibrx Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewStrategy Builder for Growth Focused Traders - Newser
What’s the recovery path for long term holders of Inhibrx Biosciences Inc.Risk-Managed Trade Alerts for Consistency - Newser
Published on: 2025-08-01 16:27:04 - metal.it
Why Inhibrx Biosciences Inc. stock attracts strong analyst attentionShort Term Gain Strategy with AI Logic - Newser
How does Inhibrx Biosciences Inc. compare to its industry peersFinancial News Tips To Watch Now - jammulinksnews.com
Intrinsic Value of Inhibrx Biosciences Inc. Stock: Is It Undervalued or OvervaluedBuy Strategy with Smart Exit Timing - Newser
How Inhibrx Biosciences Inc. stock performs during market volatilityIn-Depth Stock Trading Volume Analysis - Newser
Sectors Driving Future Growth for Inhibrx Biosciences Inc. StockLong-Term Allocation Strategy Summary Breakdown - Newser
Reversal indicators forming on Inhibrx Biosciences Inc. stockEarly Entry Planner for Swing Candidates - Newser
Is Inhibrx Biosciences Inc. Starting a New UptrendHigh Yield Stock Screening Results Explained - metal.it
Bollinger Bands Show Potential Breakout in Inhibrx Biosciences Inc.Oversold Recovery Opportunity Stocks Attract Buyers - metal.it
Inhibrx Biosciences Inc. Nearing Breakout Level After BounceInvestment Plan With Growth Optimization Finalized - metal.it
Inhibrx Biosciences Inc. Flashes Rebound Signal in Oversold ConditionAI Screening for Swing Trade Picks Finds Momentum - metal.it
Is Inhibrx Biosciences Inc. Forming a Consolidation BaseTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Is Inhibrx Biosciences Inc. the Top Chart Pick This WeekHigh Accuracy Alerts for ROI Traders Detected - metal.it
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):